FAAB

Berlin Cures advances fight against Long COVID on a pan-European level

Retrieved on: 
Thursday, November 23, 2023
Science, Cardiology, Biotechnology, Research, Optical, Health, COVID-19, Clinical Trials, Patient, FAAB, Heart failure, Phase, Glaucoma, Pharmaceutical industry, Employment agency, Long, Long COVID

Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is expanding its Phase II clinical trial into a pan-European, multi-center collaboration in the fight against Long COVID.

Key Points: 
  • Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is expanding its Phase II clinical trial into a pan-European, multi-center collaboration in the fight against Long COVID.
  • In the event of positive results, Berlin Cures is aiming for a larger Phase III study, which is a prerequisite for the approval of BC 007.
  • In Long COVID, a considerable proportion of the diseases are due to the presence of fAABs.
  • Berlin Cures aims to pioneer the development of a treatment based on BC 007 that addresses the core of fAAB-associated diseases, such as Long COVID, heart failure and glaucoma.

EQS-News: Berlin Cures advances fight against Long COVID on a pan-European level

Retrieved on: 
Thursday, December 14, 2023
Phase, Glaucoma, FAAB, Heart failure, Patient, Pharmaceutical industry, Employment agency, Long COVID, Long

Berlin, Germany, 23 November 2023 – Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is expanding its Phase II clinical trial into a pan-European, multi-center collaboration in the fight against Long COVID.

Key Points: 
  • Berlin, Germany, 23 November 2023 – Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is expanding its Phase II clinical trial into a pan-European, multi-center collaboration in the fight against Long COVID.
  • In the event of positive results, Berlin Cures is aiming for a larger Phase III study, which is a prerequisite for the approval of BC 007.
  • In Long COVID, a considerable proportion of the diseases are due to the presence of fAABs.
  • Berlin Cures aims to pioneer the development of a treatment based on BC 007 that addresses the core of fAAB-associated diseases, such as Long COVID, heart failure and glaucoma.

EQS-News: Berlin Cures takes next step in battle against Long COVID

Retrieved on: 
Tuesday, October 17, 2023
Partnership, FAAB, Aptamer, Recovery, Education, COVID, BMBF, Safety, Biotechnology, Phase, Uniklinikum Aachen, German, Patient, Federal Ministry of Health (Germany), Pharmaceutical industry, Long COVID, Research

Berlin, Germany, 10 October 2023 – Berlin Cures, a biotechnology firm specializing in the neutralization of functional autoantibodies (fAABs), is extending its collaboration with Uniklinikum Erlangen in the fight against Long COVID.

Key Points: 
  • Berlin, Germany, 10 October 2023 – Berlin Cures, a biotechnology firm specializing in the neutralization of functional autoantibodies (fAABs), is extending its collaboration with Uniklinikum Erlangen in the fight against Long COVID.
  • This partnership represents a significant step forward in the development of BC 007, Berlin Cures’ leading drug candidate for treating Long COVID and other autoimmune diseases.
  • As an accredited research center for Long COVID, Uniklinikum Erlangen will help Berlin Cures compile significant data on the efficacy and safety of BC 007 for patients with Long COVID.
  • Additionally, we are thrilled to be part of Berlin Cures' Phase II clinical trial, BLOC.”

EQS-News: Berlin Cures starts Long COVID Phase II Trial – first patients admitted

Retrieved on: 
Monday, July 3, 2023
Specialization, University, TopoTarget, Clinical trial, Toxicology, CMO, FAAB, Patient, Medpace, Annual Review of Pharmacology and Toxicology, Hospital, Phase, Therapy, Pharmaceutical industry, Medical device, Long COVID, Pharmacology

Berlin, Germany, 03 July 2023 – Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), has officially started its Phase II clinical trial in the indication Long COVID.

Key Points: 
  • Berlin, Germany, 03 July 2023 – Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), has officially started its Phase II clinical trial in the indication Long COVID.
  • The start of the Phase II clinical trial marks an important milestone in the further development of Berlin Cures’ lead drug candidate BC 007.
  • The current clinical trial will provide meaningful and robust results on the efficacy and tolerability of BC 007 in patients suffering from Long COVID.
  • “With the inclusion of patients in the clinical Phase II trial in Long COVID, we are jointly taking the next important step to advance the development of BC 007.”

Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth

Retrieved on: 
Thursday, June 15, 2023
Heart failure, LCS, CSO, Karlsruhe Institute of Technology, Biotechnology, Silence Therapeutics, Research, Doctor of Philosophy, AstraZeneca, Molecular biology, FAAB, Patient, Growth, Health, Phase, Long, Pharmaceutical industry, Long COVID

BERLIN, June 15, 2023 /PRNewswire/ -- Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is pleased to announce the appointment of its new Chief Executive Officer (CEO), Dr. Oliver von Stein. He assumes the role with immediate effect and will work closely with Berlin Cures' co-founder Dr. Johannes Müller, who will hand over his CEO duties to drive the company's research activities as the new Chief Science Officer (CSO). Dr. Müller, an accomplished physician, researcher, and innovator, has been instrumental in the development of BC 007.

Key Points: 
  • "We are excited to welcome Dr. Oliver von Stein as our new CEO to drive the next phase of innovation and growth at Berlin Cures," said Rainer Böhm, Chairman of the Board of Directors.
  • By tackling the root cause, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue."
  • Dr. Oliver von Stein said: "I'm truly honored to be joining the esteemed team at Berlin Cures during this pivotal moment.
  • Dr. Johannes Mueller added: "I am very pleased to welcome Dr. Oliver von Stein to Berlin Cures.

Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth

Retrieved on: 
Thursday, June 15, 2023
Heart failure, LCS, CSO, Karlsruhe Institute of Technology, Biotechnology, Silence Therapeutics, Research, Doctor of Philosophy, AstraZeneca, Molecular biology, FAAB, Patient, Growth, Health, Phase, Long, Pharmaceutical industry, Long COVID

BERLIN, June 15, 2023 /PRNewswire/ -- Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is pleased to announce the appointment of its new Chief Executive Officer (CEO), Dr. Oliver von Stein. He assumes the role with immediate effect and will work closely with Berlin Cures' co-founder Dr. Johannes Müller, who will hand over his CEO duties to drive the company's research activities as the new Chief Science Officer (CSO). Dr. Müller, an accomplished physician, researcher, and innovator, has been instrumental in the development of BC 007.

Key Points: 
  • "We are excited to welcome Dr. Oliver von Stein as our new CEO to drive the next phase of innovation and growth at Berlin Cures," said Rainer Böhm, Chairman of the Board of Directors.
  • By tackling the root cause, Berlin Cures emerges as one of the pioneering entities committed to addressing this critical issue."
  • Dr. Oliver von Stein said: "I'm truly honored to be joining the esteemed team at Berlin Cures during this pivotal moment.
  • Dr. Johannes Mueller added: "I am very pleased to welcome Dr. Oliver von Stein to Berlin Cures.